Received Apr 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | — | — |
covid-19; tired; congested; Initial information received on 09-Mar-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves a female patient of unknown age who had covid-19, tired and congested after being treated with SARS-COV-2 (OMICRON JN.1) recombinant spike protein (Nuvaxovid). The patient's past medical history, medical treatment(s), vaccination(s), family history, concomitant medications were not provided. On an unknown date in Apr-2025, the patient started taking SARS-COV-2 (OMICRON JN.1) recombinant spike protein dispersion for injection (strength: unknown) as unknown dose and frequency (route: unknown) for COVID-19 immunisation. On an unknown date in Jul-2025, the patient experienced covid-19 (COVID-19, onset: Jul-2025 and latency: approximately 3 months) (batch and expiry date: unknown). The patient experienced tired (Fatigue, onset: Jul-2025 and latency: approximately 3 months) (batch and expiry date: unknown). The patient experienced congested (Upper respiratory tract congestion, onset: Jul-2025 and latency: approximately 3 months) (batch and expiry date: unknown). Action taken: Not applicable. The date of last administration was Apr-2025. Corrective treatment: Not reported. Event outcome: Unknown for COVID-19, Fatigue and Upper respiratory tract congestion.
Comments: NONE